Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).

@article{Barreto2017RandomizedMT,
  title={Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).},
  author={Andrew D. Barreto and Gary A. Ford and Loren F Shen and Claudia Pedroza and Jon E. Tyson and Chunyan Cai and Mohammad H Rahbar and James C. Grotta},
  journal={Stroke},
  year={2017},
  volume={48 6},
  pages={
          1608-1616
        }
}
BACKGROUND AND PURPOSE We conducted a randomized exploratory study to assess safety and the probability of a favorable outcome with adjunctive argatroban, a direct thrombin-inhibitor, administered to recombinant tissue-type plasminogen activator (r-tPA)-treated ischemic stroke patients. METHODS Patients treated with standard-dose r-tPA, not receiving endovascular therapy, were randomized to receive no argatroban or argatroban (100 μg/kg bolus) followed by infusion of either 1 (low dose) or 3… CONTINUE READING

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?

Jong S Kim
  • Journal of stroke
  • 2019
VIEW 8 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Intravenous thrombolysis for acute ischemic stroke : new evidence and focus

DENG Ben-qiang
  • 2018
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 27 REFERENCES

Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.

M. Saqqur, Ken Uchino, +9 authors for Clotbust Investigators
  • Stroke
  • 2007
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

: analysis of the National Institute of Neurological Disorders and Stroke tissue - type plasminogen activator trials

WN Whiteley, J Emberson, +3 authors E Bluhmki
  • 2014